In United States v. Skrmetti, the Supreme Court ruled that Tennessee’s ban on gender-affirming care for minors was not unconstitutional—the first case of its kind on which the court has ruled.

An investigational drug developed by Eolo Pharma is showing promise in animal experiments and an early human trial. It could eventually be an alternative or add-on to popular GLP-1 medications.

House Democrats sent letters to the potential buyers of the genetic testing company, asking how they plan to protect customer genetic data under a change of ownership.

So-called “less-lethal” weapons like those that have been used against demonstrators in Los Angeles can cause severe, lasting harm like nerve or brain damage or blindness. They can also kill.

Paradromics, a brain-computer-interface startup, inserted its brain implant in a person—briefly—in an early test of its technology.

Scientists were able to create a bespoke treatment for KJ Muldoon’s rare genetic disorder within six months. It could be a blueprint for potentially life-saving, gene-editing Crispr therapies.

With the active ingredients in drugs like Ozempic and Zepbound no longer in shortage, access to medicine for millions who had come to rely on compounded versions is increasingly uncertain.